Omeros (OMER) Retained Earnings (2010 - 2026)
Omeros recorded quarterly Retained Earnings of -$857.6 million in Q1 2026, up 6.14% quarter-over-quarter from -$913.7 million in Q4 2025, and up 9.13% year-over-year from -$785.9 million in Q1 2025.
Omeros' Retained Earnings history runs 17 years deep, the most recent figure standing at -$857.6 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 9.13% year-over-year to -$857.6 million; the TTM figure through Mar 2026 stood at -$857.6 million (up 9.13% YoY), while the FY2025 annual figure was -$913.7 million, changed 0.37% from the prior year.
- Retained Earnings came in at -$857.6 million for Q1 2026 at Omeros, up from -$913.7 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$635.7 million in Q4 2022 to a low of -$1.0 billion in Q3 2025.
- A 5-year average of -$814.6 million and a median of -$790.7 million in 2024 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings gained 21.51% in 2022 and dropped 20.81% in 2024, its largest moves.
- Omeros' Retained Earnings stood at -$635.7 million in 2022, then decreased by 18.53% to -$753.5 million in 2023, then slipped by 20.81% to -$910.3 million in 2024, then decreased by 0.37% to -$913.7 million in 2025, then gained by 6.14% to -$857.6 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$857.6 million, -$913.7 million, and -$1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | -857.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -857.64 Mn |
| Dec 31, 2025 | -913.70 Mn |
| Sep 30, 2025 | -1.00 Bn |
| Jun 30, 2025 | -969.23 Mn |
| Mar 31, 2025 | -943.81 Mn |
| Dec 31, 2024 | -910.35 Mn |
| Sep 30, 2024 | -878.99 Mn |
| Jun 30, 2024 | -846.76 Mn |
| Mar 31, 2024 | -790.71 Mn |
| Dec 31, 2023 | -753.53 Mn |
| Sep 30, 2023 | -744.46 Mn |
| Jun 30, 2023 | -706.71 Mn |
| Mar 31, 2023 | -669.42 Mn |
| Dec 31, 2022 | -635.72 Mn |
| Sep 30, 2022 | -764.45 Mn |
| Jun 30, 2022 | -746.99 Mn |
| Mar 31, 2022 | -716.15 Mn |
| Dec 31, 2021 | -683.13 Mn |
| Sep 30, 2021 | -963.76 Mn |
| Jun 30, 2021 | -941.05 Mn |
| Mar 31, 2021 | -912.46 Mn |
| Dec 31, 2020 | -872.67 Mn |
| Sep 30, 2020 | -835.40 Mn |
| Jun 30, 2020 | -796.94 Mn |
| Mar 31, 2020 | -763.64 Mn |
| Dec 31, 2019 | -734.61 Mn |
| Sep 30, 2019 | -705.39 Mn |
| Jun 30, 2019 | -688.92 Mn |
| Mar 31, 2019 | -674.47 Mn |
| Dec 31, 2018 | -650.13 Mn |
| Sep 30, 2018 | -626.59 Mn |
| Jun 30, 2018 | -587.12 Mn |
| Mar 31, 2018 | -553.42 Mn |
| Dec 31, 2017 | -523.37 Mn |
| Sep 30, 2017 | -506.82 Mn |
| Jun 30, 2017 | -499.34 Mn |
| Mar 31, 2017 | -484.98 Mn |
| Dec 31, 2016 | -469.89 Mn |
| Sep 30, 2016 | -450.26 Mn |
| Jun 30, 2016 | -436.29 Mn |
| Mar 31, 2016 | -423.68 Mn |
| Dec 31, 2015 | -403.14 Mn |
| Sep 30, 2015 | -383.32 Mn |
| Jun 30, 2015 | -363.40 Mn |
| Mar 31, 2015 | -346.72 Mn |
| Dec 31, 2014 | -328.05 Mn |
| Sep 30, 2014 | -307.33 Mn |
| Jun 30, 2014 | -289.01 Mn |
| Mar 31, 2014 | -271.02 Mn |
| Dec 31, 2013 | -254.37 Mn |
| Sep 30, 2013 | -252.53 Mn |
| Jun 30, 2013 | -238.66 Mn |
| Mar 31, 2013 | -225.07 Mn |
| Dec 31, 2012 | -214.58 Mn |
| Sep 30, 2012 | -206.84 Mn |
| Jun 30, 2012 | -193.57 Mn |
| Mar 31, 2012 | -185.03 Mn |
| Dec 31, 2011 | -176.13 Mn |
| Sep 30, 2011 | 165.93 Mn |
| Jun 30, 2011 | 159.42 Mn |
| Dec 31, 2010 | -147.59 Mn |